SMS Lifesciences Share Price

Haleos Labs Limited, formerly, SMS Lifesciences India Limited, is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph. Eur / IP, Famotidine USP / Ph. Eur / IP, Sildenafil Citrate USP / Ph. Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph. Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. Its intermediate offerings include Ranitidine HCl Intermediates, Rizatriptan Intermediates and Imidapril Intermediates. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center is at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private Limited.As of 15 Jun 2026, SMS Lifesciences share price is ₹1,405.60. The stock opened at ₹1,399.60, compared to its previous close of ₹1,403.10. During today's trading session, SMS Lifesciences share price moved in the range of ₹1,380.20 to ₹1,429.90, with an average price of ₹1,405.05 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,380.20 and a high of ₹1,429.90. On the performance front, SMS Lifesciences share price has increased by 1.40% over the last six months and is up 18.82% on a year-on-year basis.

The market capitalization of SMS Lifesciences is ₹410 Crs, with a P/E ratio of 23.0 and a dividend yield of 0.11%.